tag:blogger.com,1999:blog-2047195573424044176.post2273561803183695208..comments2023-10-30T04:42:55.912-07:00Comments on JRG Health & Human Services Policy Update: Mixed News on Generic Drug ApprovalsJohn R. Grahamhttp://www.blogger.com/profile/09420909459359064358noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-2047195573424044176.post-14730340636302511532016-10-18T08:28:47.253-07:002016-10-18T08:28:47.253-07:00Thank you. I don't know a conference, but a bi...Thank you. I don't know a conference, but a bill: The 21st Century Cures Act which would address the problem you mention. It has passed the House, is hung up in the Senate, and may be revisited in the lame-duck session.John R. Grahamhttps://www.blogger.com/profile/09420909459359064358noreply@blogger.comtag:blogger.com,1999:blog-2047195573424044176.post-56084553690051092052016-10-17T15:29:21.271-07:002016-10-17T15:29:21.271-07:00John--
This is an important subject, and should b...John--<br /><br />This is an important subject, and should be repeated about quarterly. The FDA is chronically behind the whole context of healthcare. Isn't there an industry conference to propose substantial changes to the way the FDA conducts its review processes. Of particular interest to me as the rare diseases for which there are too few patients to provide a full control set, and where the treatment is often genetic or related to stem cells or other tissue-based approach. Not a typical chemistry-based drug. Do you know where that is?<br /><br />Cheers...<br /><br />Wanda J. Jones<br />San Franciscowanda j. jonesnoreply@blogger.com